Navigation Links
Patients use OTC NSAIDs even when they have a high risk of serious side effects
Date:6/12/2013

cations from the use of NSAIDs by high risk patients are a common cause of unplanned hospital admissions related to medications, which in turn constitute a significant public health problem. Two previous Dutch observational studies have shown that approximately 5% of all unplanned hospital admissions are associated with ADEs, of which 40-46% are potentially preventable.2

This study was among adults registered with four Dutch general practitioners (GPs). Two samples of different patient populations were selected: (i) a random sample of adults (general population), and (ii) a sample of adult patients with a high risk of developing a serious ADE from NSAID use (high-risk population).

Patients' risk profiles were determined using their electronic medical records. All included patients were sent a questionnaire regarding their use of OTC NSAIDs in the four weeks prior to participation. In the high-risk population, of the 265 patients who agreed to participate, 33 (13%) had used an OTC NSAID. In the general population sample, of the 120 patients who agreed to participate, 35 (29%) had used an OTC NSAID.

Over 30% of OTC NSAID users had used the treatment for more than seven days in the high risk-population, and over 20% in the general population. OTC NSAIDs were used in a dosage exceeding the recommended daily maximum dose by 3% and 9% in the high-risk and the general populations respectively.

Musculoskeletal complaints formed the most commonly cited reason for OTC NSAID use in the high-risk group; 67% gave this as a reason for use.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Page: 1 2

Related biology news :

1. Exercise for stroke patients brains
2. Experts find epigenetic changes moderate reality distortion in schizophrenia patients
3. Study finds taking probiotics has benefits for patients in hospitals
4. Oncologists are stressed and have difficulty discussing death with patients -- Ben-Gurion U. study
5. Addition of bevacizumab to initial treatment for brain tumors does not extend patients lives
6. Nanomedicines impact on patients under the microscope
7. Vitamin C does not lower uric acid levels in gout patients
8. PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
9. AegisCare Offers Specialized Home Health Care for Dementia and Alzheimers Patients
10. University of Maryland Medical Center launches genetic-testing program for cardiac patients
11. Gene expression test distinguishes btw breast cancer patients at high & low risk of late recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  Valencell, Inc., a leader in ... one of 18 "Showcase Companies" representing North ... annual CED Tech Venture Conference on September 16-17 th ... Center in Raleigh, North Carolina . ... a discussion during the "Digital Health Spotlight Sector" on ...
(Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
(Date:9/15/2014)... a common epilepsy drug to a morphine regimen can ... Moreover, the combination can reduce the dosage of the ... of pain researchers at Indiana University. , The result ... pain, a difficult-to-treat condition often felt in the arms ... "There is a huge unmet need for better treatments ...
Breaking Biology News(10 mins):Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
... ago, the German Physical Society (DPG) has introduced the ... interdisciplinary applications of physics. The Prize, endowed with 5000 ... instrument to encourage research in this direction. This ... Max Planck Institute for Evolutionary Biology in Pln. He ...
... , New Rochelle, NY -- A novel method for ... help advance research on tissue engineering and regeneration, as ... Part C, Methods, a peer-reviewed journal from Mary Ann ... free online at the Tissue Engineering website ...
... proteins that actively pump a wealth of molecules across ... functions in humans. Genetic defects in ABC transporters can ... cystic fibrosis, and certain ABC transporters also cause resistance ... increased amounts of ABC transporters that pump chemotherapeutic substances ...
Cached Biology News:'Young Scientist Award for Socio- and Econophysics 2012' for Arne Traulsen 2
(Date:9/15/2014)... classical phase transitionsthink solid, liquid, and gasbut ... temperature drops. If phase transitions occur at ... reigns, subtle fluctuations can dramatically transform a ... Department of Energy,s Brookhaven National Laboratory and ... landscape of absolute zero to isolate and ...
(Date:9/15/2014)... JOSE, Calif. , Sept. 15, 2014 /PRNewswire/ ... Proposals (RFP) for flexible, printed product demonstrators (demos) ... a two-stage RFP process with pre-proposals due on ... January 2015.  Funds for proposals ultimately selected are ... and have a significant cost share by the ...
(Date:9/15/2014)... of researchers led by Northeastern University has developed ... junctions and a variety of nanocarbon structures in ... easily scalable, which will allow the researchers to ... use in applications ranging from electronic devices to ... to sports equipment. , Their findings were published ...
(Date:9/15/2014)... 2014 Research and Markets has announced ... Product, by Services, by Technology, by Application - Global Forecast ... Whole Exome Sequencing (WES) is next-generation technology used for strategically ... The exome, which is the total of all exons of ... is actually converted into proteins after translation. It is responsible ...
Breaking Biology Technology:Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3
... Annual Revenues Up, Net Loss Down, Cash Position Strong, as Pipeline ... ... (Nasdaq: EXEL ) today reported financial results for the full,year and ... $113.5 million, compared to $98.7 million in,2006. The increase in revenues for ...
... PALO ALTO, Calif., Feb. 14 Telik, Inc.,(Nasdaq: ... webcast will,be held on Thursday, February 21, 2008 at ... release earlier that day of the company,s,financial results for ... The conference call will be accessible via Telik,s ...
... Executives from Senexis,and O2H, both located in Cambridge, ... synthetic and computational chemistry services to the drug,discovery ... "We believe our collaboration with O2H leverages the ... search for new,therapeutics to treat ageing-related diseases by ...
Cached Biology Technology:Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 2Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 3Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 4Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 5Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 6Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 7Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 8Exelixis Announces Full Year and Fourth Quarter 2007 Financial Results 9Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration 2